NeurOp, Inc. is a clinical-stage biotechnology company developing new medicines for central nervous system disorders, including stroke, severe pain, subarachnoid hemorrhage (SAH), and treatment-resistant depression. Its technology targets the GluN2B subunit of neuronal NMDA receptors and its potential therapeutic benefit. Multi-year funding from the NIH supports NeurOp's research and development programs for NP10679, its drug candidate for the prevention of ischemic damage during a stroke or subarachnoid hemorrhage (SAH) and severe pain. For more information, please visit www.neuropinc.com.